OncoGenex Pharmaceuticals, Inc. today announced final results from a Phase 1 trial. The primary purpose of this trial was to evaluate the safety and tolerability of OGX-427 up to doses of 1000 mg for the rehabilitation of various solid tumors. patients enrolled had a interpretation of castration resistant prostate cancer, breast cancer, ovarian cancer or non-small cell lung cancer.

More: - The rest...